170 related articles for article (PubMed ID: 34252351)
1. Novel natural inhibitors targeting B-RAF(V600E) by computational study.
Wu B; Zhang Z; Dou G; Lv X; Ge J; Wang H; Xie H; Zhu D
Bioengineered; 2021 Dec; 12(1):2970-2983. PubMed ID: 34252351
[TBL] [Abstract][Full Text] [Related]
2. Computational Study of Novel Natural Inhibitors Targeting O
Yang L; Li W; Zhao Y; Zhong S; Wang X; Jiang S; Cheng Y; Xu H; Zhao G
World Neurosurg; 2019 Oct; 130():e294-e306. PubMed ID: 31203065
[TBL] [Abstract][Full Text] [Related]
3. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
[TBL] [Abstract][Full Text] [Related]
4. Computational study of novel natural inhibitors targeting aminopeptidase N(CD13).
Ge J; Wang Z; Cheng Y; Ren J; Wu B; Li W; Wang X; Su X; Liu Z
Aging (Albany NY); 2020 May; 12(9):8523-8535. PubMed ID: 32388498
[TBL] [Abstract][Full Text] [Related]
5. Helix-Coil Transition Signatures B-Raf V600E Mutation and Virtual Screening for Inhibitors Directed Against Mutant B-Raf.
Bandaru S; Sumithnath TG; Sharda S; Lakhotia S; Sharma A; Jain A; Hussain T; Nayarisseri A; Singh SK
Curr Drug Metab; 2017 Jul; 18(6):527-534. PubMed ID: 28472910
[TBL] [Abstract][Full Text] [Related]
6. Computational study on new natural compound agonists of stimulator of interferon genes (STING).
Zhong S; Li W; Bai Y; Wu B; Wang X; Jiang S; Zhao Y; Ren J; Li H; Jin R
PLoS One; 2019; 14(5):e0216678. PubMed ID: 31120925
[TBL] [Abstract][Full Text] [Related]
7. Computational study on natural compounds inhibitor of c-Myc.
Ren J; Huangfu Y; Ge J; Wu B; Li W; Wang X; Zhao L
Medicine (Baltimore); 2020 Dec; 99(50):e23342. PubMed ID: 33327259
[TBL] [Abstract][Full Text] [Related]
8. Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer.
Yao H; Sun Q; Zhu J
Arch Pharm (Weinheim); 2016 Oct; 349(10):808-815. PubMed ID: 27624806
[TBL] [Abstract][Full Text] [Related]
9. Resistance mechanism of the oncogenic β3-αC deletion mutation in BRAF kinase to dabrafenib and vemurafenib revealed by molecular dynamics simulations and binding free energy calculations.
Niu Y; Zhang Y; Yao X
Chem Biol Drug Des; 2019 Feb; 93(2):177-187. PubMed ID: 30225883
[TBL] [Abstract][Full Text] [Related]
10. Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies.
Anbar HS; El-Gamal MI; Tarazi H; Lee BS; Jeon HR; Kwon D; Oh CH
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1712-1726. PubMed ID: 32962435
[TBL] [Abstract][Full Text] [Related]
11. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Selective Small Molecule Degraders of BRAF-V600E.
Han XR; Chen L; Wei Y; Yu W; Chen Y; Zhang C; Jiao B; Shi T; Sun L; Zhang C; Xu Y; Lee MR; Luo Y; Plewe MB; Wang J
J Med Chem; 2020 Apr; 63(8):4069-4080. PubMed ID: 32223235
[TBL] [Abstract][Full Text] [Related]
13. Biochemical Characterization of Full-Length Oncogenic BRAF
Cope N; Novak B; Candelora C; Wong K; Cavallo M; Gunderwala A; Liu Z; Li Y; Wang Z
Chembiochem; 2019 Nov; 20(22):2850-2861. PubMed ID: 31152574
[TBL] [Abstract][Full Text] [Related]
14. Molecular dynamics simulation, free energy calculation and structure-based 3D-QSAR studies of B-RAF kinase inhibitors.
Yang Y; Qin J; Liu H; Yao X
J Chem Inf Model; 2011 Mar; 51(3):680-92. PubMed ID: 21338122
[TBL] [Abstract][Full Text] [Related]
15. Discovery of EBI-907: A highly potent and orally active B-Raf(V600E) inhibitor for the treatment of melanoma and associated cancers.
Lu B; Cao H; Cao J; Huang S; Hu Q; Liu D; Shen R; Shen X; Tao W; Wan H; Wang D; Yan Y; Yang L; Zhang J; Zhang L; Zhang L; Zhang M
Bioorg Med Chem Lett; 2016 Feb; 26(3):819-823. PubMed ID: 26739779
[TBL] [Abstract][Full Text] [Related]
16. Insight into the Binding of DFG-out Allosteric Inhibitors to B-Raf Kinase Using Molecular Dynamics and Free Energy Calculations.
Coronel L; Granadino-Roldán JM; Pinto M; Tomas MS; Pujol MD; Rubio-Martinez J
Curr Comput Aided Drug Des; 2015; 11(2):124-36. PubMed ID: 26135342
[TBL] [Abstract][Full Text] [Related]
17. Computational study on novel natural inhibitors targeting c-MET.
Hou Y; Xie H; Dou G; Yang W; Ge J; Zhou B; Ren J; Li J; Wang J; Zhang Z; Wang X
Medicine (Baltimore); 2021 Sep; 100(38):e27171. PubMed ID: 34559105
[TBL] [Abstract][Full Text] [Related]
18. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the differences in activity between hydroxycycloalkyl N1 substituted pyrazole derivatives as inhibitors of B-Raf kinase by using docking, molecular dynamics, QM/MM, and fragment-based de novo design: study of binding mode of diastereomer compounds.
Caballero J; Alzate-Morales JH; Vergara-Jaque A
J Chem Inf Model; 2011 Nov; 51(11):2920-31. PubMed ID: 22011048
[TBL] [Abstract][Full Text] [Related]
20. Structural optimization of imidazothiazole derivatives affords a new promising series as B-Raf V600E inhibitors; synthesis, in vitro assay and in silico screening.
Ammar UM; Abdel-Maksoud MS; Ali EMH; Mersal KI; Ho Yoo K; Oh CH
Bioorg Chem; 2020 Jul; 100():103967. PubMed ID: 32470760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
